Empowered Funds LLC Buys 15,563 Shares of Medtronic PLC $MDT

Empowered Funds LLC lifted its stake in Medtronic PLC (NYSE:MDT) by 8.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 198,488 shares of the medical technology company’s stock after buying an additional 15,563 shares during the period. Empowered Funds LLC’s holdings in Medtronic were worth $17,199,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of MDT. Madison Asset Management LLC increased its position in shares of Medtronic by 15.0% in the fourth quarter. Madison Asset Management LLC now owns 195,216 shares of the medical technology company’s stock valued at $18,752,000 after acquiring an additional 25,527 shares during the period. Ticino Wealth purchased a new stake in shares of Medtronic during the fourth quarter worth about $2,049,000. First Eagle Investment Management LLC boosted its holdings in shares of Medtronic by 0.4% during the fourth quarter. First Eagle Investment Management LLC now owns 9,775,234 shares of the medical technology company’s stock worth $939,009,000 after purchasing an additional 40,196 shares during the period. KBC Group NV grew its stake in shares of Medtronic by 5.2% in the fourth quarter. KBC Group NV now owns 430,508 shares of the medical technology company’s stock worth $41,354,000 after purchasing an additional 21,384 shares during the last quarter. Finally, Cerity Partners LLC grew its stake in shares of Medtronic by 12.7% in the fourth quarter. Cerity Partners LLC now owns 791,015 shares of the medical technology company’s stock worth $75,988,000 after purchasing an additional 89,111 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.26% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on MDT shares. Jefferies Financial Group reaffirmed a “hold” rating and set a $88.00 price target on shares of Medtronic in a research report on Thursday, June 4th. JPMorgan Chase & Co. cut their price objective on Medtronic from $100.00 to $86.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Robert W. Baird decreased their target price on Medtronic from $93.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, June 4th. Piper Sandler reaffirmed a “neutral” rating and issued a $85.00 price target on shares of Medtronic in a research note on Tuesday, June 16th. Finally, Mizuho dropped their price target on Medtronic from $120.00 to $100.00 and set an “outperform” rating for the company in a research note on Wednesday, June 3rd. Eighteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Medtronic has an average rating of “Moderate Buy” and a consensus target price of $98.83.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic completed its $650 million acquisition of SPR Therapeutics and launched the ViaVerte system at ASPN 2026. The deal expands the company’s non-opioid pain-management portfolio and could provide a new avenue for growth in pain therapy. Medtronic Completes $650 Million SPR Deal And Launches ViaVerte
• Positive Sentiment: Brokerages have assigned Medtronic an average “Moderate Buy” recommendation, indicating that analysts generally see upside or support at current valuation levels. Medtronic Given Average Recommendation of Moderate Buy
• Neutral Sentiment: Valuation analysis suggests MDT is near fair value on a discounted-cash-flow basis but may screen as undervalued on earnings multiples. Shares are near a five-year low after an approximately 25% five-year decline, which may attract value investors, though the analysis notes execution and growth risks. Medtronic Stock May Be Fairly Valued As Shares Sit Near A 5 Year Low
• Neutral Sentiment: MDT recently outperformed the broader market in a session that ended at $84.22, reflecting improving short-term momentum but offering no major fundamental catalyst by itself. Medtronic Outpaces Stock Market Gains
• Negative Sentiment: Medtronic initiated a voluntary Class II recall of its DLP One-Piece Pediatric Arterial Cannula after two complaints involving loose foreign material with trace blood levels. The recall may raise product-quality, regulatory and reputational concerns, although its impact on company-wide results is not yet clear. Is Medtronic Fairly Valued After Its Pediatric Cannula Recall?

Medtronic Stock Performance

Medtronic stock opened at $86.87 on Wednesday. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The stock’s 50 day simple moving average is $80.46 and its two-hundred day simple moving average is $87.25. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. The stock has a market cap of $111.20 billion, a price-to-earnings ratio of 23.29, a PEG ratio of 2.26 and a beta of 0.56.

Medtronic (NYSE:MDT) last announced its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The firm had revenue of $9.81 billion during the quarter, compared to analyst estimates of $9.62 billion. During the same quarter in the prior year, the company earned $1.62 EPS. The business’s revenue was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, analysts expect that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 17th. Shareholders of record on Friday, June 26th were issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 3.3%. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. The ex-dividend date was Friday, June 26th. Medtronic’s dividend payout ratio is currently 77.21%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).